Senseonics Holdings, Inc. (SENS): Price and Financial Metrics

Senseonics Holdings, Inc. (SENS): $1.13

0.01 (+0.89%)

POWR Rating

Component Grades














  • Growth is the dimension where SENS ranks best; there it ranks ahead of 62.87% of US stocks.
  • SENS's strongest trending metric is Value; it's been moving up over the last 179 days.
  • SENS's current lowest rank is in the Stability metric (where it is better than 0.84% of US stocks).

SENS Stock Summary

  • With a price/sales ratio of 67.06, Senseonics Holdings Inc has a higher such ratio than 96.9% of stocks in our set.
  • SENS's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 4.84% of US stocks.
  • Revenue growth over the past 12 months for Senseonics Holdings Inc comes in at 176.32%, a number that bests 95.3% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to Senseonics Holdings Inc, a group of peers worth examining would be CLSN, NVCN, ABEO, SMTC, and BLI.
  • Visit SENS's SEC page to see the company's official filings. To visit the company's web site, go to

SENS Valuation Summary

  • In comparison to the median Healthcare stock, SENS's price/earnings ratio is 108.77% lower, now standing at -3.2.
  • Over the past 69 months, SENS's price/sales ratio has gone down 6313.4.
  • SENS's price/sales ratio has moved down 6313.4 over the prior 69 months.

Below are key valuation metrics over time for SENS.

Stock Date P/S P/B P/E EV/EBIT
SENS 2021-08-31 165.5 -5.7 -3.2 -3.3
SENS 2021-08-30 157.3 -5.4 -3.1 -3.1
SENS 2021-08-27 167.2 -5.8 -3.2 -3.3
SENS 2021-08-26 160.2 -5.5 -3.1 -3.2
SENS 2021-08-25 153.5 -5.3 -3.0 -3.1
SENS 2021-08-24 151.1 -5.2 -2.9 -3.0

SENS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • SENS has a Quality Grade of D, ranking ahead of 13.13% of graded US stocks.
  • SENS's asset turnover comes in at 0.084 -- ranking 71st of 76 Measuring and Control Equipment stocks.
  • A, ASTC, and MTD are the stocks whose asset turnover ratios are most correlated with SENS.

The table below shows SENS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.084 0.401 -5.465
2021-03-31 0.098 0.360 -5.709
2020-12-31 0.127 -3.509 -2.449
2020-09-30 0.158 -2.814 -1.660
2020-06-30 0.144 -2.385 -1.365
2020-03-31 0.165 -1.997 -1.885

SENS Stock Price Chart Interactive Chart >

Price chart for SENS

SENS Price/Volume Stats

Current price $1.13 52-week high $4.58
Prev. close $1.12 52-week low $0.77
Day low $1.10 Volume 2,918,759
Day high $1.16 Avg. volume 10,089,365
50-day MA $1.55 Dividend yield N/A
200-day MA $2.67 Market Cap 523.49M

Senseonics Holdings, Inc. (SENS) Company Bio

Senseonics Holdings, Inc. focuses on the design, development, and commercialization of glucose monitoring systems for people with diabetes. The company was founded in 1996 and is based in Germantown, Maryland.

SENS Latest News Stream

Event/Time News Detail
Loading, please wait...

SENS Latest Social Stream

Loading social stream, please wait...

View Full SENS Social Stream

Latest SENS News From Around the Web

Below are the latest news stories about Senseonics Holdings Inc that investors may wish to consider to help them evaluate SENS as an investment opportunity.

Senseonics Holdings (SENS) Gets a Hold Rating from BTIG

In a report released today, Marie Thibault from BTIG reiterated a Hold rating on Senseonics Holdings (SENS – Research Report). The company's shares closed last Wednesday at $1.83, close to its 52-week low of $1.40. According to, Thibault is a 5-star analyst with an average return of 22.6% and a 38.7% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Edwards Lifesciences, and Irhythm Technologies. The word on The Street in general, suggests a Hold analyst consensus rating for Senseonics Holdings with a $1.90 average price target.

Howard Kim on TipRanks | March 2, 2022

Analysts’ Opinions Are Mixed on These Technology Stocks: Avid Technology (AVID), Lattice Semiconductor (LSCC) and Senseonics Holdings (SENS)

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Avid Technology (AVID – Research Report), Lattice Semiconductor (LSCC – Research Report) and Senseonics Holdings (SENS – Research Report). Avid Technology (AVID) In a report released today, Steve Frankel from Colliers Securities maintained a Hold rating on Avid Technology. The company's shares closed last Tuesday at $29.00. According to, Frankel is a 2-star analyst with an average return of -5.5% and a 36.2% success rate. Bauser covers the Healthcare sector, focusing on stocks such as Apollo Medical Holdings, Chembio Diagnostics, and Semler Scientific.

Catie Powers on TipRanks | March 2, 2022

Senseonics ticks up on Q4 earnings beat

Senseonics (NYSE:SENS) shares ticked up today on fourth-quarter results that came in ahead of the consensus forecast. The Germantown, Maryland-based company posted revenues of $4 million for the three months ended Dec. 31, 2021, representing sales growth of 2.6% from the same period in 2020. Adjusted to exclude one-time items, earnings per share were 1¢, […] The post Senseonics ticks up on Q4 earnings beat appeared first on Drug Delivery Business .

Drug Delivery Business | March 2, 2022

Senseonics Holdings (SENS) Beats Q4 Earnings and Revenue Estimates

Senseonics (SENS) delivered earnings and revenue surprises of 133.33% and 0.20%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 2, 2022

Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2021 Financial Results

GERMANTOWN, Md.--(BUSINESS WIRE)--Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today reported financial results for the quarter and full year ended December 31, 2021. Recent Highlights & Accomplishments: Received approval from the Food and Drug Administration (FDA) for the Eversense® E3 CGM System, offering patients: Fu

Business Wire | March 1, 2022

Read More 'SENS' Stories Here

SENS Price Returns

1-mo -25.17%
3-mo -38.92%
6-mo -65.02%
1-year -42.64%
3-year -44.06%
5-year -31.93%
YTD -57.68%
2021 206.26%
2020 -4.83%
2019 -64.63%
2018 -2.63%
2017 -0.37%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0826 seconds.